Newsgroup: it.economia.borsa
Titolo: CELL

http://www.ilnuovomercato.it/?p=19283
 
 
 

 
http://www.ilnuovomercato.it/?p=19283
 
 
LA SOCIETà HA SMENTITO
INTANTO......................
 
Cell Therapeutics, Inc. (NASDAQ:CTIC) faces another Investor Investigation 
over possible new Securities Laws Violations
February 21, 2012 | Author: ShareholdersFoundation | Posted in Investor 
Relations
  a.. b.. c..
  d.. 0
  inShareAn new investigation on behalf of investors in shares of Cell 
Therapeutics , Inc. ( NASDAQ:CTIC ) was announced over new potential 
securities laws violations by certain officers and directors at Cell 
Therapeutics in connection with its statements in regards to its New Drug 
Application for Pixuvri(TM).
 
Investors who purchased shares of Cell Therapeutics, Inc. ( NASDAQ : CTIC ) 
in 2011 or 2012, have certain options and should contact the Shareholders 
Foundation at mail(at)
shareholdersfoundation.com
 or call 
+1(858) 779 - 1554
.
 
The new investigation by a law firm focuses on possible claims on behalf of 
purchasers of the securities of Cell Therapeutics, Inc. (NASDAQ:CTIC) 
concerning whether a series of statements regarding Cell Therapeutics' 
business , its prospects and its operations were materially false and 
misleading at the time they were made. Specifically the new investigation 
focuses on
 
On January 30, 2012, Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) 
announced that it has withdrawn its New Drug Application ("NDA") for Pixuvri 
(pixantrone) for the treatment of relapsed or refractory aggressive 
non-Hodgkin's lymphoma ("NHL") in patients who failed two or more lines of 
prior therapy.
 
Cell Therapeutics, Inc said the NDA was withdrawn because, after 
communications with the FDA, Cell Therapeutics, Inc needed additional time 
to prepare for the review of the Pixuvri NDA by the FDA's Oncologic Drugs 
Advisory Committee at its February 9, 2012 meeting. Prior to withdrawing the 
NDA, Cell Therapeutics, Inc requested that the FDA consider rescheduling the 
review of the Pixuvri NDA to the Oncologic Drugs Advisory Committee meeting 
to be held in late March. The FDA was unable to accommodate Cell 
Therapeutics' request to reschedule, and given the April 24, 2012 
Prescription Drug User Fee Act date, the only way to have Pixuvri possibly 
considered at a later ODAC meeting was for CTI to withdraw and later 
resubmit the NDA. Cell Therapeutics said it plans to resubmit the NDA in 
2012.
As a result of the withdrawal of the NDA, the FDA will no longer make a 
decision.
 
Cell Therapeutics already faces a lawsuit a filed by investors who invested 
in the time frame between March 25, 2008 and March 22, 2010. The plaintiff 
in that complaint alleges that defendants, among other things, failed to 
disclose that the Special Protocol Assessment ("SPA") with theFDA for 
pixantrone was invalidated in March 2008;
 
Shares of Cell Therapeutics, Inc. (NASDAQ:CTIC) fell since its 1:6 split on 
May 16, 2011 from slightly over $2.20 per share to slightly $1 per share.
 
Those who purchased shares of Cell Therapeutics, Inc. (NASDAQ:CTIC) and 
currently hold those NASDAQ:CTIC shares, may have certain options and should 
contact the Shareholders Foundation.
 
Contact:
Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: 
+1-(858)-779-1554
 
Fax: 
+1-(858)-605-5739
 
mail(at)
shareholdersfoundation.com